ANDA 214337, held by Aspiro. Sugammadex Sodium.
As of Nov 16, 2026, ANDA 214337 (Sugammadex Sodium), held by Aspiro, was first approved by FDA on Jun 9, 2023, with 1 approved supplement and 0 published complete response letters.
Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. Additional pediatric use information is approved for Merck Sharp & Dohme LLC's BRIDION (sugammadex) injection. However, due to Merck Sharp & Dohme LLC's marketing exclusivity rights, this drug product is not labeled with that information.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 9, 2023 | Original application | Approved |
| Sugammadex SodiumEQ 200MG BASE/2ML (EQ 100MG BASE/ML) · solution;intravenous | Sugammadex Sodium | Rx |
| Sugammadex SodiumEQ 500MG BASE/5ML (EQ 100MG BASE/ML) · solution;intravenous | Sugammadex Sodium | Rx |
| Oct 8, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 9, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters